• FDA accepted Bayer’s supplemental NDA for Kerendia to treat adults with chronic kidney disease without diabetes.
• Filing backed by Phase III FIND-CKD data showing slower eGFR decline versus placebo, with a 0.7 mL/min/1.73 m²/year difference.
• Trial also cut risk on a kidney-cardiovascular composite endpoint, hazard ratio 0.77.
• Safety broadly matched prior studies; hyperkalemia occurred in 17% on Kerendia versus 13.3% on placebo.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20261007583229) on October 08, 2026, and is solely responsible for the information contained therein.